Solna, Stockholm, Sweden – March 12, 2025 – Barnik Invest’s Portfolio Company, Cell4Cure AB, a pioneering Swedish biotech company developing innovative immune tolerance therapies, last week announced its strategic partnership with Bartlett Hill Partners LLC, a leading advanced therapies consulting group based in Boston, to spearhead its North American business development initiatives.
Cell4Cure’s proprietary antigen-specific dendritic cell tolerance platform is designed to address the critical challenge of Anti-Drug Antibodies (ADAs), which can significantly diminish the tolerance and efficacy of biologic therapies. By mitigating the impact of ADAs, Cell4Cure’s technology aims to enhance the therapeutic potential of existing biologics across a range of indications. Through this collaboration, Cell4Cure will be introducing the platform to international pharma companies residing in North America and having marketed biologics treating patients with e.g. cancer, anti-inflammation, hemophilia. The platform could also be used for patients with autoimmune diseases or transplanted patients at risk of rejection.
Bartlett Hill Partners is led by John Manzello, a globally recognized executive with extensive expertise in advanced therapies. Leveraging his decades of industry experience, Mr. Manzello will provide strategic counsel and drive Cell4Cure’s business development activities in North America, fostering key partnerships and accelerating the company’s growth.
“We at Barnik Invest are incredibly proud to see our portfolio company, Cell4Cure, taking this significant step towards expanding its North American market presence,” said Hamid Bakhshi, CEO of Barnik Invest Group. “The partnership with Bartlett Hill Partners, under the expert guidance of John Manzello, represents a significant moment for Cell4Cure. This strategic alliance provides Cell4Cure access to expertise and network that will be instrumental in introducing the innovative platform to potential partners and accelerating its adoption.”
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: info@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for small Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully-owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development phase to commercialization, enabling them to achieve positive cash flows or successful exits and ultimately enhancing patient well-being and improving human health worldwide. For more information visit www.barnikinvest.com.
